The latest price target for Protagenic Therapeutics (NASDAQ:PTIX) was reported by Maxim Group on October 29, 2021. The analyst firm set a price target for $4.00 expecting PTIX to rise to within 12 months (a possible 463.38% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Protagenic Therapeutics (NASDAQ:PTIX) was provided by Maxim Group, and Protagenic Therapeutics initiated their buy rating.

There is no last upgrade for Protagenic Therapeutics

There is no last downgrade for Protagenic Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagenic Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagenic Therapeutics was filed on October 29, 2021 so you should expect the next rating to be made available sometime around October 29, 2022.

While ratings are subjective and will change, the latest Protagenic Therapeutics (PTIX) rating was a initiated with a price target of $0.00 to $4.00. The current price Protagenic Therapeutics (PTIX) is trading at is $0.71, which is within the analyst’s predicted range.